A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...
AML: Acute myeloid leukemia; CLL: C-type lectin-like molecule; CXCR: CXC chemokine receptor; N/A: Not applicable; NF: Nuclear factor. Acute myeloid leukemia (AML) remains incurable for the ...
David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...
Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.
A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...
Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.
Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...